The U.S. Department of Health and Human Services, Office for Civil Rights is proud to launch the Information Is Powerful Medicine campaign.
[More]
Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients – the next question is to figure out how to match the right treatments with the right patients.
[More]
The need to add tissue preserving therapies to the prostate cancer treatment continuum was highlighted prominently at the 108th Annual Meeting of the American Urological Association, in San Diego.
[More]
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
[More]
Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.
[More]
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.
[More]
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.
[More]
Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication.
[More]
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology.
[More]
Men experience a higher burden of disease and lower life expectancy than women, but policies focusing on the health needs of men are notably absent from the strategies of global health organisations, according to a Viewpoint article in this week's Lancet.
[More]
Regularly taking prescription painkillers, also known as opioids, is associated with a higher risk of erectile dysfunction (ED) in men, according to a study published online today in the journal Spine.
[More]
Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer.
[More]
The Prostate Cancer Foundation today announced that it is funding two more Young Investigators in China to lead innovative research projects within the country and expand PCF's global knowledge exchange on game-changing research in prostate cancer.
[More]
Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).
[More]
Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Umeå University in a new study.
[More]
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
[More]
UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities - the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-Cap) and the physician-reported Charlson Comorbidity Index - can successfully target prostate patients who would not benefit from biopsy to discover possible cancer.
[More]
The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.
[More]
Sporting events can bring a community together, such as when the Louisville Cardinals won the NCAA championship and University of Louisville campus was filled with camaraderie.
[More]
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.
[More]